RCH Achieves AWS Life Sciences Competency
Leading Cloud solutions exclusively for Life Sciences teams that accelerate discovery, optimize costs and ensure scalability and compliance in AWS.
Design of Experiments (DOE) is one of the most essential tools scientists can use to accelerate timelines, optimize costs, maximize insights, and minimize risks when making informed decisions. For example, clinical trials employ a variety of experimental designs to determine whether a new medicine effectively improves patients’ lives and to what extent.
If you are developing therapies with the goal of entering human clinical trials, the expertise of statisticians in the field of Experimental Design is indispensable. Regulatory agencies require a thorough understanding of the study’s structure: the number of patients involved, how outcomes are measured, the statistical power necessary to detect a significant effect, and the methods you plan to use for data analysis and reporting. To meet these demands, BioPharma companies must engage a clinical statistics CRO or build an in-house clinical team that includes statisticians, programmers, operations specialists, and data managers. Although these teams may begin small, as trials progress, organizational needs and staffing often scale quickly.
So, why do agencies invest so much time to ensure these plans are robust? As we know, health authorities have a mandate to ensure that medicines are both safe and effective. The public relies on these agencies to minimize risks, guarantee the quality of medicines, and confirm their efficacy for intended uses.
If this level of statistical rigor is required for clinical trials, why don’t more companies prioritize a similar approach with non-clinical statistics? The current economic climate in BioPharma might provide some insight. In 2024 alone, more than 140 layoff announcements have led to a substantial reduction in the workforce, putting pressure on companies to prioritize short-term savings over long-term gains. With a focus on cost-cutting, roles or functions, like non-clinical statisticians, that may be perceived as optional, are often the first to be scaled back or excluded.
However, consider the benefits of applying non-clinical statistical expertise from the early stages of development.
How can we leverage this expertise from the very beginning of the product lifecycle?
How can we design experimental plans that seamlessly guide us through process development, characterization, analytical validation, tech transfer, and, ultimately, commercialization?
By starting with a clear understanding of our desired outcomes, it’s possible to maximize resource efficiency and avoid costly missteps throughout R&D.
Non-clinical statistics can significantly streamline the development process. With a well-executed preclinical statistical plan, companies can craft an IND package that stands up to regulatory scrutiny, reduce the volume of experiments needed for complete process or method qualification for the BLA, and create a robust narrative that supports product development history, specification setting, and process comparability designs. What do all these benefits have in common? They reflect not an ‘extra’ but a strategic investment in efficiency that can smooth and accelerate medicine development.
Engaging non-clinical statisticians, much like clinical statisticians, is crucial to the success of your BioPharma organization. Leveraging tools such as Design of Experiments not only brings rigor to research and development, but also contributes to substantial savings in time, resources, and inefficiency. In today’s competitive and cost-conscious BioPharma landscape, employing non-clinical statistics is a forward-thinking, yet critical approach, that ensures every development dollar is spent effectively, bringing high-quality treatments to patients sooner.
Learn more about how RCH Solutions can support your non-clinical statistical efforts with the expertise of industry veterans, including seasoned non-clinical statisticians like JoAnn Coleman.
Managing and analyzing macromolecular and protein-ligand structural data is a crucial yet challenging task in the complex world of Life Sciences Research. To address this need, RCH Solutions brings extensive expertise in deploying and managing Chemical Computing Group’s (CCG) PSILO platform to streamline the protein structure management processes for Biotech and Pharma companies of all sizes.
Whether for startups, mid-size, or global players, RCH Solutions ensures that customers maximize the efficiency and effectiveness of their structural data management through seamless implementation, support, and ongoing optimization of PSILO.
What is PSILO?
PSILO, or Protein Silo, is a sophisticated database system designed by CCG to provide a consolidated repository for proprietary and public macromolecular and protein-ligand structural information. It is tailored to meet the needs of Research organizations by offering a systematic way to register, annotate, track, and disseminate structural data derived from experimental and computational sources.
Key Features of PSILO
Benefits of Using PSILO with RCH Solutions’ Expertise
As an experienced scientific computing service provider, RCH Solutions specializes in helping Biotech and Pharma companies of all sizes optimize PSILO for maximum impact.
General Applications and Use Cases
Conclusion
RCH Solutions’ expertise with PSILO ensures that Biotech and Pharma companies of all sizes can effectively manage and utilize protein-ligand and macromolecular structural data. By centralizing, organizing, and securing structural information, RCH Solutions enhances the benefits of CCG’s PSILO platform, driving more efficient workflows, fostering collaboration, and advancing scientific Research. Whether a company is focused on drug discovery, innovation, or collaborative Research, RCH Solutions ensures that their PSILO deployment is fine-tuned and right-sized for optimal performance, empowering scientists to focus on the science and their next big breakthrough.
Let’s chat! For more information about optimizing or leveraging CCG PSILO at your Biotech or Pharma, get in touch with our team at www.rchsolutions.com or marketing@rchsolutions.com.
Sources:
Chemical Computing Group (CCG) | Computer-Aided Molecular Design
PSILO® – Structure Database – CCG Video Library
AWS HealthOmics is a comprehensive suite of services offered by Amazon Web Services (AWS) designed to support the management, analysis, and integration to help bioinformaticians, researchers, and scientists manage and gain insights from large sets of genomic and biological data.
It streamlines the processes of storing, querying, and analyzing this information, supporting faster discovery and insight generation for both research and clinical applications. AWS HealthOmics aims to facilitate breakthroughs in these areas by providing scalable, secure, and efficient Cloud-based solutions, and is composed of three core elements:
AWS HealthOmics includes features designed to unlock the full potential of genomic and biological data, with the following benefits aligned to AWS HealthOmics’ informational page. It securely combines the multi-omics data of individuals with their medical history to facilitate more personalized care. It uses purpose-built data stores to support large-scale analysis and collaborative research across populations. It accelerates science and medicine with Ready2Run workflows or the ability to bring your own private bioinformatics workflows. Additionally, it protects patient privacy with HIPAA eligibility and built-in data access and logging.
Below are some of the key technical features of AWS HealthOmics:
Below are some of the noteworthy benefits of AWS HealthOmics for Life Sciences teams:
AWS HealthOmics represents a significant advancement in the management and analysis of omics data, providing a powerful and flexible Cloud-based solution for Life Sciences organizations. By leveraging the comprehensive services offered by AWS, researchers and clinicians can overcome the challenges associated with large-scale omics data, driving innovation and improving patient outcomes. Whether for genomics, proteomics, or any other omics field, AWS HealthOmics offers the tools and infrastructure needed to unlock the full potential of omics research.
As an AWS Advanced Tier Service Partner, RCH Solutions is the premier partner to help Life Sciences organizations leverage AWS HealthOmics and fully optimize entire AWS environments. With over three decades of experience exclusively in the Life Sciences sector, we’ve supported 7 of the top 10 global pharmaceutical companies and more than 50 start-ups and mid-size Life Sciences teams across all stages of development and maturity. Currently finalizing our distinguished AWS Life Sciences Competency designation, our expertise ensures we deliver cutting-edge solutions tailored to the specific needs of the Life Sciences.
Overcoming Common Roadblocks in Biopharma to Harness the Power of AI: Insights from RCH Solutions
In the rapidly evolving field of life sciences, artificial intelligence (AI) has emerged as a transformative force, promising to revolutionize biopharmaceutical research and development. However, many biopharma companies, regardless of their size, encounter significant roadblocks that hinder the effective integration and utilization of AI. As a specialized scientific computing provider with an exclusive focus on the life sciences, RCH Solutions has identified several common challenges and offers strategies to overcome these obstacles, enabling organizations to fully leverage the power of AI.
Common Roadblocks in Biopharma
Strategies to Overcome These Roadblocks
Use Cases of AI in Biopharma
Conclusion
The integration of AI in biopharma holds immense potential to transform research, development, and operational processes. However, overcoming common roadblocks such as data silos, poor data quality, integration challenges, skills gaps, and regulatory hurdles is crucial for realizing this potential. By implementing strategic solutions and leveraging the expertise of specialized scientific computing providers like RCH Solutions, biopharma companies can successfully harness the power of AI to drive innovation and achieve their scientific and business objectives.
For more insights and support on integrating AI in your biopharma organization, visit RCH Solutions.
Driving Success from Discovery to Commercialization
Throughout the BioPharma industry, many think statistics are critical only to human clinical trials. However, Non-Clinical Statistics plays a pivotal role in moving assets through discovery, research, and development—all the way to commercialization. Though lesser known, these specialized statisticians are essential to ensuring that every aspect of a drug’s journey from lab bench to market is grounded in rigorous, data-driven decision-making.
The Power of Non-Clinical Statistics
At RCH Solutions, there is a keen awareness that drug development is a complex, high-stakes process. Success rates hover around 7-8%1, and setbacks in the early development or manufacturing stages can result in costly delays. A skilled non-clinical statistician can distinguish between a program that stalls and moves forward confidently. Non-clinical statisticians specialize in addressing challenges that arise long before clinical trials begin. They support diverse teams across Discovery, Research, and Chemistry, Manufacturing, and Controls (CMC), ensuring your program is designed to answer the right questions from the outset.
Early-Stage Impact: Target Identification and Method Development
Designing the suitable experiments in the early stages of drug discovery is critical. Non-clinical statisticians help BioPharma organizations by guiding the setup of studies that provide reliable, actionable data. Whether designing NGS studies to identify targets or working with chemists to optimize analytical methods, non-clinical statisticians help ensure that your data answers the questions that matter.
With proper statistical guidance, teams could save time and resources by quantifying value and avoiding chasing the wrong or inconclusive outcomes. A non-clinical statistician helps to mitigate this risk, maximizing the value of your early-stage research and putting you on the path to success.
Optimizing Manufacturing Processes and Ensuring Quality
Regarding manufacturing, non-clinical statisticians are critical players in developing robust process understanding and product characterization. They collaborate with engineers and chemists to design experiments that optimize processes, minimize variation, and consistently produce high-quality products.
Statistical methods can also be applied to issues like impurity reduction, process transfer to Contract Manufacturing Organizations (CMOs), or method validation—tasks vital to smooth regulatory submission and approval. In this way, Non-Clinical Statistics mitigate risk and keep the drug development pipeline moving forward.
Bridging the Gap Between Science and Regulation
Regulatory submissions can be a significant hurdle in getting a product to market. A well-designed statistical plan can help address concerns from agencies regarding impurities, method validation, or product stability. Non-clinical statisticians, equipped with the ability to model complex scenarios and collaborate with scientific teams, play a critical role in ensuring the readiness of an asset for regulatory approval.
Their expertise enables your team to present data compellingly and scientifically soundly, meeting the rigorous expectations of regulatory bodies. From INDs to BLAs and NDAs, they ensure your program’s foundation is built on solid, data-driven decisions.
Partnering with RCH Solutions: The Non-Clinical Statistics Advantage
At RCH Solutions, we understand Non-Clinical Statistics critical role in BioPharma’s success. Our team of expert statisticians works collaboratively with your R&D and CMC teams to ensure programs are designed for optimal outcomes, not bottlenecks. From target selection to regulatory approval, we deliver data-driven insights that save time and resources, minimizing trial and error. By leveraging our expertise, you can streamline processes, enhance production, and confidently move your drug development program forward—ultimately bringing life-changing medicines to patients faster.
Get in touch with our team of expert statisticians today to learn more about our Non-Clinical Statistics services.
1 Source: Biotechnology Innovation Organization (BIO), Informa, QLS Advisors, Clinical Development Success Rates 2011-2020.
Cryo-Electron Microscopy (CryoEM) continues to become an increasingly important technique in the field of structural biology, offering unprecedented insights into the molecular structures of biomolecules. Its ability to visualize complex macromolecular assemblies at near-atomic resolution has made it a transformative tool in drug discovery and development within the BioPharma industry. However, the complexity of CryoEM data analysis requires specialized expertise and a robust computational infrastructure, built on best practices and for scale. This is where a comprehensive and specialized advanced and scientific computing provider like RCH Solutions, with deep CryoEM expertise, can add immense value, and also where single-focused providers with only Cryo-EM specialization fall short.
Understanding CryoEM: A Brief Overview
CryoEM involves the flash-freezing of biomolecules in a thin layer of vitreous ice, preserving their native state for high-resolution imaging. This technique bypasses the need for crystallization, which is a significant limitation in X-ray crystallography. CryoEM is particularly advantageous for studying large and flexible macromolecular complexes, membrane proteins, and dynamic conformational states of biomolecules.
Key benefits of CryoEM in BioPharma include:
Challenges in CryoEM Data Analysis
While CryoEM holds immense upside, the data analysis process is complex and computationally intensive. The challenges a team might experience include:
Adding Value with RCH Solutions: CryoEM Expertise
RCH Solutions, a specialized scientific computing provider, offers comprehensive CryoEM support, addressing the unique computational and analytical needs of BioPharma companies. Here’s how RCH Solutions can add value:
1. High-Performance Computing (HPC) Infrastructure:
2. Data Management & Storage Solutions:
3. Advanced Software and Workflow Integration:
4. Expert Consultation and Support:
5. Cloud Computing Capabilities:
6. Training and Knowledge Transfer:
Real-World Impact: Success Stories
Several BioPharma companies have already benefited from the expertise of RCH Solutions in CryoEM. For instance:
Conclusion
CryoEM is a transformative technology in the BioPharma industry, offering unparalleled insights into the molecular mechanisms of diseases and therapeutic targets. However, the complexity of CryoEM data analysis necessitates specialized computational expertise and infrastructure. Check out additional CryoEM-focused content from our team here.
RCH Solutions, with its deep CryoEM expertise and comprehensive support services, empowers BioPharma companies to harness the full potential of CryoEM, driving innovation and accelerating drug discovery and development. Partnering with RCH Solutions ensures that BioPharma companies can navigate the challenges of CryoEM data analysis efficiently, ultimately leading to better therapeutic outcomes and advancements in the field of structural biology.
“Jupyter Notebooks have changed the narrative on how Scientists leverage code to approach data, offering a clean and direct paradigm for developing and testing modular code without the complications of more traditional IDEs.”
These versatile tools offer an interactive environment that combines code execution, data visualization, and narrative text, making it easier to share insights and collaborate effectively. To make the most of Jupyter Notebooks, it is essential to follow best practices and optimize workflows. Here’s a comprehensive guide to help you master your use of Jupyter Notebooks.
Jupyter Notebooks can be a powerful tool that can significantly enhance your data science and research workflows. By following the best practices and optimizing your use of notebooks, you can create organized, efficient, and reproducible projects. Whether you’re analyzing data, developing machine learning models, or sharing insights with your team, Jupyter Notebooks provide a versatile platform to achieve your goals.
RCH can efficiently deploy and administer Notebooks to free up the customer teams to focus on code/algorithms/data. Additionally, our team can add logic in the Public Cloud to shutdown Notebooks (and other Dev type resources) when not in use to ensure cost control and optimization—and more. Our team is committed to helping Biopharma organizations leverage both proven and cutting-edge technologies to achieve goals. Contact RCH today to learn more about support for success with Jupyter Notebooks and beyond.
In the rapidly evolving Life Sciences landscape, leveraging advanced tools and technologies is crucial for BioPharmas to stay competitive and drive innovation. The Posit Suite’s powerful components—Workbench, Connect, and Package Manager—offer a comprehensive platform to significantly enable data analysis, collaboration, and package management capabilities.
Understanding The Posit Suite
The Posit Suite comprises three core components:
Insights and Best Practices for The Posit Suite
The Workbench is the heart of The Posit Suite, where data scientists and analysts spend most of their time. To maximize its potential:
Connect is designed to bridge the gap between data creation and consumption. Here’s how to make the most of it:
Managing packages and dependencies is a critical aspect of reproducible research and development. The Package Manager simplifies this process:
Tips for Maximizing the Posit Suite in Biopharma
Integrate The Posit Suite with existing workflows and systems. Whether connecting to a Laboratory Information Management System (LIMS) or integrating with cloud infrastructure, seamless integration enhances efficiency and reduces the learning curve.
Invest in training and support for teams. Familiarize users with the suite’s features and best practices. Partnering with experts like RCH Solutions can provide invaluable guidance and troubleshooting.
Stay current with the latest updates and features of The Posit Suite. Regularly updating tools ensures access to the latest advancements and security patches.
Conclusion
The Posit Suite offers biopharma organizations a powerful and versatile platform to enhance their data analysis, collaboration, and package management capabilities. By optimizing Workbench, Connect, and Package Manager and following best practices and tips, one can unlock the full potential of The Posit Suite, driving innovation and efficiency in organizations.
At RCH Solutions, the team is committed to helping Biopharma organizations leverage both proven and cutting-edge technologies to achieve goals. Contact RCH today to learn more about support for success with The Posit Suite and beyond.
Cloud technologies remain a highly cost-effective solution for computing. In the early days, these technologies signaled the end of on-premise hardware, floor space and potentially staff. Now, the focus has shifted to properly optimizing the Cloud environment to continue reaping the cost benefits. This is particularly the case for Biotech and Pharma companies that require a great deal of computing power to streamline drug discovery and research.
Managing costs related to your computing environment is critical for emerging Biotechs and Pharmas. As more data is collected, new compliance requirements emerge, and novel drugs are discovered and move into the next stages of development, your dependence on the Cloud will grow accordingly. It’s important to consider cost optimization strategies now and keep expenses under control. Optimizing your Cloud environment with the right tools, options, and scripts will help you get the most value and allow you to grow uninhibited.
Let’s explore some top cost containment tips that emerging Biotech and Pharma startups can implement.
No one wants to pay for more than they need. However, when you’re an emerging company, your computing needs are likely to evolve quickly as you grow.
This is where it helps to understand instance types and apply them to specific workloads and use cases. For example, using a smaller instance type for development and testing environments can save costs compared to using larger instances meant for production workloads.
Spot instances are spare compute capacity offered by Cloud providers at a significant discount compared to on-demand instances. You can use these instances for workloads that can tolerate interruptions or for non-critical applications to save costs.
Another option is to choose an auto-scaling approach that will allow you to automatically adjust your computing based on the workload. This reduces costs by only paying for what you use and ensuring you don’t over-provision resources.
Guardrails are policies or rules companies can implement to optimize their Cloud computing environment. Examples of guardrails include:
Working with solutions like AWS Control Tower or Turbot can help you set up these cost control guardrails and stick to a budget. Ask the provider what cost control options they offer, such as budgeting tools or usage tracking. From there, you can collaborate on an effective cost optimization strategy that aligns with your business goals. Your vendor may also work with you to implement these cost management strategies, as well as check in with you periodically to see what’s working and what needs to be adjusted.
Similar to electronics consuming power when plugged in but not in use, your computing environment can suck up costs and resources even during downtime. One way to mitigate usage and save on costs is to create custom scripts that automatically turn off computing resources when not in use.
To start, identify which resources can be turned off (e.g., databases, storage resources). From there, you can review usage patterns and create a schedule for turning off those resources, such as after-hours or on weekends.
Scripting languages such as Python or Bash can create scripts that will turn off these resources according to your strategy. Once implemented, test the scripts to ensure they’re correct and will produce the expected cost savings.
Many vendors, including market-leader AWS, offer special programs to help new customers get acclimated to the Cloud environment. For instance, AWS Jumpstart helps customers accelerate their Cloud adoption journey by providing assistance and best practices. Workshops, quick-start help, and professional services are part of the program. They also offer funding and credits to help customers start using AWS in the form of free usage tiers, grants for nonprofit organizations, and funding for startups.
Other vendors may offer similar programs. It never hurts to ask what’s available.
Fast-tracking toward the Cloud starts with great relationships. Working with an established IT company like RCH that specializes in Biotechs and Pharmas and also has established relationships with Cloud providers, including as a Select Consulting Partner with AWS, as well as associated technologies gives you the best of both worlds.
Cloud cost optimization strategies shouldn’t be treated as an afterthought or put off until you start growing.
It’s best practice to instill cost control guardrails now and think about how you can scale your Cloud computing in the future so that cost doesn’t become a growth inhibitor.
In an industry that moves at the speed of technology, RCH Solutions brings a wealth of specialized expertise to help you thrive. We apply our experience in working with BioPharma companies and startups to ensure your budget, computing capacity, and business goals align.
We invite you to schedule a one-hour complimentary consultation with SA on Demand, available through the AWS Marketplace, to learn more about cost optimization strategies in the Cloud and how they support your business. Together, we can develop a Cloud computing environment that balances the best worlds of budget and breakthroughs.
https://docs.aws.amazon.com/AWSEC2/latest/UserGuide/instance-types.html
As a business owner or leader, you quickly learn that employees are the backbone of your company. And this has never been more true with the exceptional talent we have and continually acquire at RCH.
But in today’s competitive and challenging job market, it’s becoming increasingly difficult for many businesses to attract and retain top talent —or “A” players, as we often say. Workers across all industries are voluntarily leaving their jobs due to burnout, a desire for a career change, and/or pursuing a more ideal work-life balance by going out on their own.
Call it the “Great Resignation”, a newfound “Gig Economy” or something else, it’s more critical now than ever that your employee acquisition and retention strategy is a key focus, if it’s not already.
And Life Science organizations are not immune to this trend. We are all just experiencing its effects in different ways, given the unique skill sets and demands required to be a competitive leader in this space. I’m thankful to say, however, RCH has fared better than many. Here’s why.
Our culture has been, and always will be, built on a people-first mentality.
While attracting and retaining the right Bio-IT talent can be difficult, the flexible and balanced work structure we’ve followed since our company’s inception, combined with our incredibly high standards for our people and our outcomes have helped us mitigate these typical challenges.
And candidly, they set us apart and make RCH an employer and partner of choice.
In my experience, an organization’s ability to attract—and more importantly retain—the best specialists, goes hand-in-hand with the execution of truly unmatched scientific computing outcomes.
Some of the reasons I think we’ve had success in this area, in no particular order, include:
1. Our EE Training & Development Plan
At RCH, continuous learning and improvement is one of our core values. We invest in the success and expertise of our team and actively encourage and enable them to build their skills in meaningful ways—even if that means carving out work time to do so.
We aim to help improve employees’ existing competencies and cross functional skills while simultaneously developing newer ones to support the individual’s professional goals. We have unique and individualized training programs, relevant mentorship opportunities, and other career development and advancement strategies to support our team members.
2. Our Continuous Recruitment & People-First Approach
Our rolling recruitment strategy continuously accepts and reviews applications for job openings throughout the year, rather than waiting for a specific hiring season, role or deadline. With continuous recruitment, we build a pool of highly qualified, top talent candidates that will complement and/or add to the skills that exist within our deep bench of professionals, and we can effectively and quickly fill any vacancies with the right people—a key focus of ours.
Continuous recruitment also helps us plan for future workforce needs and stay competitive by having target candidates already identified and prequalified for future roles or project needs that may arise.
3. Our Focus on Hiring and Retaining ‘A’ players
In my career, I’ve seen far too many organizations with a Quantity over Quality strategy, simply throwing more people at problems. But a Quality over Quantity approach will win every time. The difference? The former will experience slow adoption which can stall outcomes with major impacts to short- and long-term objectives. The latter propels outcomes out of the gates, circumventing crippling mistakes along the way. For this reason and more, I’m a big believer in attracting and retaining only “A” talent.
The best talent and the top performers (quality) will always outshine and out deliver a bunch of average ones (quantity). Which is why acquiring and retaining only top talent that can effectively address specialized challenges should be your key focus if it isn’t already.
4. Our Access to Cutting-Edge Technology & Encouraging Creativity and Innovation
Bio-IT professionals thrive on innovation and new technology, so we always aim to provide ours with access to the latest tools and software, and encourage them to experiment with new technologies that could improve processes and workflows for our customers. We foster an environment that truly encourages creativity and innovation and provide our team members with the freedom to explore new ideas and take risks, while also setting clear goals and objectives to ensure alignment with organizational priorities.
This approach benefits both our customers and our team members by enabling the possibility for further accelerated breakthroughs, and satisfying their innate desire to leverage innovation to advance science and customer outcomes.
5. Our Core Values & Culture
Employees want to work for a company that values their contributions and creates an empowering and aspirational work environment. This can include things like recognizing employee achievements, providing opportunities for growth and development, and creating a sense of community and belonging within the workplace.
Our core values and culture do that and more, and unwaveringly represent the threads that weave together the fabric of our culture. And hiring the right people who share these core values, and building a culture around a team that embraces the RCH Solutions DNA is paramount. And more critical than ever.
6. Adhering to Our Unique Managed Services Model
Unlike static workforce augmentation services provided by big-box consultants, our dynamic, science-centered Sci-T Managed Services model delivers specialized consulting and execution tailored to meet the unique Bio-IT needs of research and development teams, on-demand. This model gives our team diversity in their work and creates opportunities to take on new challenges and projects that not only excite them, but keep their skills and their day-to-day experiences dynamic.
It’s rewarding for our team, both personally and professionally, and from a learning and development perspective, to have the exposure to a wide range of customers and environments.
Acquiring, retaining and empowering Bio-IT teams requires a commitment to creating a supportive and inclusive work environment, providing opportunities for growth and development and recognizing and rewarding accomplishments along the way.
While challenging at times, organizations that unwaveringly commit to their people, culture and mission will be able to attract and retain “A” talent, and foster an empowered work environment that will naturally drive innovation, advance the organization’s mission and propel customer outcomes.
Click below to get in touch with our team and learn more about our industry-leading Bio-IT team, our specialized approach and what sets us apart from other Bio-IT partners.
The integration of high-performance computing (HPC) in the Cloud is not just about scaling up computational power; it’s about architecting systems that can efficiently manage and process the vast amounts of data generated in Biotech and Pharma research. For instance, in drug discovery and genomic sequencing, researchers deal with datasets that are not just large but also complex, requiring sophisticated computational approaches.
However, designing an effective HPC Cloud environment comes with challenges. It requires a deep understanding of both the computational requirements of specific workflows and the capabilities of Cloud-based HPC solutions. For example, tasks like ultra-large library docking in drug discovery or complex genomic analyses demand not just high computational power but also specific types of processing cores and optimized memory management.
In addition, the cost-efficiency of Cloud-based HPC is a critical factor. It’s essential to balance the computational needs with the financial implications, ensuring that the resources are utilized optimally without unnecessary expenditure.
In Life Sciences R&D, the computational demands require sophisticated computational capabilities to extract meaningful insights. HPC plays a pivotal role by enabling rapid processing and analysis of extensive datasets. For example, HPC facilitates multi-omics data integration, combining genomics with transcriptomics and metabolomics for a comprehensive understanding of biological processes and disease. It also aids in developing patient-specific simulation models, such as detailed heart or brain models, which are pivotal for personalized medicine.
Furthermore, HPC is instrumental in conducting large-scale epidemiological studies, helping to track disease patterns and health outcomes, which are essential for effective public health interventions. In drug discovery, HPC accelerates not only ultra-large library docking but also chemical informatics and materials science, fostering the development of new compounds and drug delivery systems.
This computational power is essential not only for advancing research but also for responding swiftly in critical situations like pandemics. Additionally, HPC can integrate environmental and social data, enhancing disease outbreak models and public health trends. The advanced machine learning models powered by HPC, such as deep neural networks, are transforming the analytical capabilities of researchers.
HPC’s role in handling complex data also involves accuracy and the ability to manage diverse data types. Biotech and Pharma R&D often deal with heterogeneous data, including structured and unstructured data from various sources. The advanced data visualization and user interface capabilities supported by HPC allow for intricate data patterns to be revealed, providing deeper insights into research data.
HPC is also key in creating collaboration and data-sharing platforms that enhance the collective research efforts of scientists, clinicians, and patients globally. HPC systems are adept at integrating and analyzing these diverse datasets, providing a comprehensive view essential for informed decision-making in research and development.
In order to construct an HPC environment that is both robust and adaptable, Life Sciences organizations must carefully consider several key architectural components:
HPC in the Cloud is as crucial as its initial setup. This optimization involves strategic approaches to common challenges like data transfer bottlenecks and latency issues.
Efficiently managing computational tasks is key. This involves prioritizing workloads based on urgency and complexity and dynamically allocating resources to match these priorities. For instance, urgent drug discovery simulations might take precedence over routine data analyses, requiring a reallocation of computational resources.
But efficiency isn’t just about speed and cost; it’s also about smooth data travel. Optimizing the network to prevent data transfer bottlenecks and reducing latency ensures that data flows freely and swiftly, especially in collaborative projects that span different locations.
In sensitive Bio-IT environments, maintaining high security and compliance standards is another non-negotiable. Regular security audits, adherence to data protection regulations, and implementing robust encryption methods are essential practices.
A well-architected HPC environment in the Cloud is pivotal for advancing research and development in the Biotech and Pharma industries.
By effectively planning, considering architectural needs, and continuously optimizing the setup, organizations can harness the full potential of HPC. This not only accelerates computational workflows but also ensures these processes are cost-effective and secure.
Ready to optimize your HPC/Cloud environment for maximum efficiency and impact? Discover how RCH can guide you through this transformative journey.
Sources:
https://www.rchsolutions.com/high-performance-computing/
https://www.nature.com/articles/s41586-023-05905-z
https://www.rchsolutions.com/ai-aided-drug-discovery-and-the-future-of-biopharma/
https://www.nature.com/articles/s41596-021-00659-2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318494/
https://pubmed.ncbi.nlm.nih.gov/37702944/
https://link.springer.com/article/10.1007/s42514-021-00081-w
https://www.rchsolutions.com/resource/scaling-your-hpc-environment-in-a-cloud-first-world/ https://www.rchsolutions.com/how-high-performance-computing-will-help-scientists-get-ahead-of-the-next-pandemic/ https://www.scientific-computing.com/analysis-opinion/how-can-hpc-help-pharma-rd
https://www.rchsolutions.com/storage-wars-cloud-vs-on-prem/
https://www.rchsolutions.com/hpc-migration-in-the-cloud/
https://www.mdpi.com/2076-3417/13/12/7082
https://www.rchsolutions.com/resource/hpc-migration-to-the-cloud/
As research becomes increasingly data-driven, the need for a robust IT infrastructure, coupled with a team that can navigate the complexities of bioinformatics, is vital to progress. But what happens when your in-house Bio-IT services team encounters challenges beyond their capacity or expertise?
This is where strategic augmentation comes into play. It’s not just a solution but a catalyst for innovation and growth by addressing skill gaps and fostering collaboration for enhanced research outcomes.
The pace of innovation demands an agile team and diverse expertise. A thorough evaluation of your in-house Bio-IT team’s capabilities is the foundational step in this process. It involves a critical analysis of strengths and weaknesses, identifying both skill gaps and bottlenecks, and understanding the nuances of your team’s ability to handle the unique demands of scientific research.
For startup and emerging Biotech organizations, operational pain points can significantly alter the trajectory of research and impede the desired pace of scientific advancement. A comprehensive blueprint that includes team design, resource allocation, technology infrastructure, and workflows is essential to realize an optimal, scalable, and sustainable Bio-IT vision.
Traditional models of sourcing tactical support often clash with these needs, emphasizing the necessity of a Bio-IT Thought Partner that transcends typical staff augmentation and offers specialized experience and a willingness to challenge assumptions.
Before sourcing the right resources to support our team, it’s essential to identify where the gaps lie. Start by:
Once you’ve identified the gaps, the next step is to find the right partners to fill them. Here’s how:
Merging in-house and external teams can be challenging. However, with the right strategies, collaboration can lead to unparalleled research outcomes.
For IT professionals and decision-makers in Pharma, Biotech, and Life Sciences, the decision to augment the in-house Bio-IT team is not just about filling gaps; it’s about propelling research to new heights, ensuring that the IT infrastructure is not just supportive but also transformative.
When making this decision, consider the long-term implications. While immediate project needs are essential, think about how this augmentation will serve your organization in the years to come. Will it foster innovation? Will it position you as a leader in the field? These are the questions that will guide you toward the right choice.
Life Science research outcomes can change the trajectory of human health, so there’s no room for compromise. Augmenting your in-house Bio-IT team is a commitment to excellence. It’s about recognizing that while your team is formidable, the right partners can make them invincible. Strength comes from recognizing when to seek external expertise.
Pick the right team to supplement yours. Talk to RCH Solutions today.
Sources:
https://www.rchsolutions.com/harnessing-collaboration/
https://www.rchsolutions.com/press-release-rch-introduces-solution-offering-designed-to-help-biotech-startups/
https://www.rchsolutions.com/what-is-a-bio-it-thought-partner-and-why-do-you-need-one/
https://www.rchsolutions.com/our-people-are-our-key-point-of-difference/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652225/
https://www.forbes.com/sites/forbesbusinesscouncil/2023/01/10/three-best-practices-when-outsourcing-in-a-life-science-company/?sh=589b57a55575
https://www.cio.com/article/475353/avoiding-the-catch-22-of-it-outsourcing.html